Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)
NCT ID: NCT06377527
Last Updated: 2025-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
2000 participants
OBSERVATIONAL
2024-07-10
2037-12-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1\. To collect data on participants characteristics, disease characterization, pathology and molecular data, treatment, and outcomes for participants with gynecologic mesonephric-like adenocarcinoma (MLA).
Secondary Objectives
1. To organize clinical information to support multifaceted queries of participant characteristics, treatment, and disease outcome data and to facilitate correlation of these characteristics with participant outcome.
2. To have a single data repository kept on a secure platform that will integrate clinical information and research findings and serve as an archive for future research.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mesonephric-like Adenocarcinoma (MLA)
Particpants who agree to take part in this research, information such as your demographics (including your name, date of birth, race, etc.), medical history, surgical history, family history, social history, cancer diagnosis, primary treatment, and follow up will be collected.
Participants also have the option to agree to the use of your previously collected tumor tissue samples for future research to better understand MLA.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with a diagnosis of gynecologic mesonephric-like adenocarcinoma (MLA), mesonephric adenocarcinoma (MA), mesonephric carcinosarcoma, or mesonephric-like carcinosarcomas.
3. For patients who provide consent, they must speak and/or read English or Spanish.
Exclusion Criteria
2. Patients who are considered cognitively impaired. Assessment will be obtained based on their need of a Legally Authorized Representative.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeffrey How, MD
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jeffrey How, MD
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
MD Anderson Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2024-03342
Identifier Type: OTHER
Identifier Source: secondary_id
2023-0945
Identifier Type: -
Identifier Source: org_study_id